市場調查報告書
商品編碼
946292
脊柱生物製品市場:增長,趨勢,預測(2020-2025)Spine Biologics Market - Growth, Trends, and Forecasts (2022 - 2027) |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
在預測期內,預計脊柱生物製劑市場的複合年增長率為4%。這是由於老年人口增加,脊柱畸形的患病率增加以及植骨技術的進步。此外,退行性脊柱疾病的發生率增加,同時治療率顯著提高,並且對微創手術的偏好增加,也有助於推動市場增長。另外,椎間融合和外側椎體間直接融合是治療脊柱畸形的兩種先進的生物學機制,已在世界範圍內被外科醫生廣泛採用。此外,與生物材料發展和側身固定相關的微創程序方法是治療脊柱疾病的理想方法,該方法安全,有效並且可快速恢復並減少損傷。導致。這進一步推動了對脊椎生物製劑治療椎間盤發育,硬化症和其他脊柱相關疾病的需求。脊柱損傷在50歲以上的人中很常見,容易出現脊柱或脊柱功能障礙,並且全世界老年人口的人數不斷增加,從而增加了對疾病治療和診斷的需求。因此,上述因素將在預測期內推動脊柱生物製劑市場。
該報告調查了脊柱生物製劑市場,並提供了系統的信息,例如市場狀況,市場動態,市場細分分析,行業狀況,主要公司概況和未來前景。
The Spine Biologics Market is expected to register a CAGR of 4% during the forecast period. This is attributing to the growing geriatric population, rising prevalence of spine deformities, and technological advancements in bone grafting procedures. In addition, rising incidences of degenerative spine disorders with a significant increase in treatment rates and increasing preference for minimally invasive procedures are also fueling the growth of the market. Moreover, interbody fusion and direct lateral interbody fusion are the two advanced biological mechanisms for the treatment of the deformity of the spine and are highly adopted among surgeons globally. Furthermore, Advancements in the biomaterial and minimally invasive procedure approach associated with lateral body fusion is an ideal approach for the treatment of spine disorders as this procedure results in safe, effective, fast recovery and less injury. It further promotes the demand for spine biologics in the treatment of disc generation, sclerosis and other spine-related disorders. Spine injuries are very common among the population who are above 50 years as they are more susceptible to have structural alteration in the spine or spinal impairments thus growing geriatric population around worldwide will also promote the demand of treatment and diagnosis of the disorders. Therefore, the aforementioned factors will drive the spine biologics market in forecasted period.
Spinal allografts are estimated to witness healthy growth in the future which is attributed to several benefits associated with its usage. Spinal allografts are the allograft bone that is donated from another patient (donor) and used in the spine treatment procedure. The use of allografts in spinal fusion will eliminate the additional surgical procedure that is reduced surgery time. In addition, these are osteoconductive which means it provides a scaffold to the spine repair. Moreover, several companies are working and providing on natural bone grafts that are harvested from the donor body. For instance, Zimmer Biomet offers RegenerOss Resorbable Xenograft (natural bone grafts). Products from such international and well-established companies indicate the demand for spinal allografts in the market.
North America is expected to hold a significant market share in the global Spine Biologics Market due to the presence of the geriatric population, increasing adoption of minimally invasive procedure, and rising prevalence of spine disorders such as spondylolisthesis, spinal stenosis, and disc-related issue. As per the American Association of Neurological Surgeons, every year an estimate of 17,000 new cases of spinal cord injury reported in the United States. Thus a large number of spinal cord injury population will significantly promote the demand for the treatment of disorders wherein spinal biologics plays an important role in diagnosis and thereby driving the overall market The United States owns the largest share of Spine Biologics Market in the North America region Furthermore, well-established infrastructure, stable economic growth, growing health care expenditure is also expected to fuel the Spine Biologics Market in this region.
The Spine Biologics Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Johnson & Johnson (Depuy Synthes), Orthofix Medical Inc., Stryker Corporation, Zimmer Biomet, Arthrex, Inc., Exactech, Inc, Medtronic plc, etc.